|
No images? Click here
Medical Advisory: Benzanthine Penicillin G (Bicillin® L-A) ShortageIssued by: Dr. Azim Kasmani, MD, MSc, FRCPC, Medical Officer of Health and Commissioner The Ministry of Health has notified local public health units of an ongoing national shortage of Benzathine Penicillin G (Bicillin® L-A), the recommended first-line treatment for syphilis. We will continue to monitor the shortage and communicate updates accordingly. Health care providers should restrict use of Bicillin® L-A and use alternative treatments for syphilis as per the Public Health Agency of Canada’s (PHAC) Interim Syphilis Treatment Guidelines in the Event of a Benzathine Penicillin G (Bicillin® L-A) Shortage Use of Bicillin® L-A The Ministry recommends that public health units and health care providers restrict the use of Bicillin® L-A to:
Alternative Treatment During the Bicillin® L-A shortage only, the Ministry recommends oral doxycycline as the preferred treatment for initiating therapy in:
If there is no uncertainty regarding staging of late latent syphilis, clinicians may opt to defer initiation of treatment until the supply is restored. Clients who have already initiated their treatment course with Bicillin® L-A should complete their therapy with Bicillin® L-A according to standard guidelines. More Information Public Health nurses are available to support with the management of positive syphilis test results, including consultation on appropriate treatment options. Please call 905-688-8248 ext. 7723 to speak with a nurse. |